AC Immune (ACIU) Cash & Current Investments (2014 - 2025)
AC Immune (ACIU) reported Cash & Current Investments of $114.3 million for Q4 2025, down 39.47% year-over-year from $188.9 million in Q4 2024, and down 15.67% on a QoQ basis from $135.6 million in Q3 2025.
AC Immune (ACIU) has 12 years of Cash & Current Investments data on file, last reported at $114.3 million in Q4 2025.
- Quarterly Cash & Current Investments fell 39.47% year-over-year to $114.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $114.3 million (down 39.47% YoY) and the FY2025 annual result came in at $110.2 million, down 41.65% from the prior year.
- Cash & Current Investments fell to $114.3 million in Q4 2025 per ACIU's latest filing, from $135.6 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $125.9 billion in Q4 2021 and bottomed at -$32.8 million in Q2 2021.
- The 5-year median for Cash & Current Investments is $131.4 million (2025), against an average of $10.0 billion.
- Peak annual rise in Cash & Current Investments reached 50282.19% in 2021, while the deepest fall reached 116.85% in 2021.
- Tracing ACIU's Cash & Current Investments over 5 years: stood at $125.9 billion in 2021, then sank by 99.9% to $127.2 million in 2022, then advanced by 28.41% to $163.4 million in 2023, then advanced by 15.61% to $188.9 million in 2024, then tumbled by 39.47% to $114.3 million in 2025.
- Per Business Quant, the three latest ACIU Cash & Current Investments figures stand at $114.3 million (Q4 2025), $135.6 million (Q3 2025), and $166.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 114.35 Mn |
| Sep 30, 2025 | 135.60 Mn |
| Jun 30, 2025 | 166.31 Mn |
| Mar 31, 2025 | 161.96 Mn |
| Dec 31, 2024 | -78.06 Mn |
| Sep 30, 2024 | -79.07 Mn |
| Jun 30, 2024 | -22.68 Mn |
| Mar 31, 2024 | 38.67 Mn |
| Dec 31, 2023 | 163.40 Mn |
| Sep 30, 2023 | 84.83 Mn |
| Jun 30, 2023 | 77.39 Mn |
| Mar 31, 2023 | 108.59 Mn |
| Dec 31, 2022 | 127.25 Mn |
| Sep 30, 2022 | 66.79 Mn |
| Jun 30, 2022 | 111.32 Mn |
| Mar 31, 2022 | 188.23 Mn |
| Dec 31, 2021 | 125.89 Bn |
| Sep 30, 2021 | -32.57 Mn |
| Jun 30, 2021 | -32.79 Mn |
| Mar 31, 2021 | 71.89 Bn |
| Dec 31, 2020 | 211.16 Mn |
| Sep 30, 2020 | 218.98 Mn |
| Jun 30, 2020 | 194.55 Mn |
| Mar 31, 2020 | 287.26 Mn |
| Dec 31, 2019 | 129.92 Mn |
| Sep 30, 2019 | 154.74 Mn |
| Jun 30, 2019 | 205.13 Bn |
| Mar 31, 2019 | 172.84 Mn |
| Dec 31, 2018 | 187.36 Mn |
| Dec 31, 2017 | 126.07 Mn |
| Sep 30, 2017 | 158.18 Mn |
| Jun 30, 2017 | 154.48 Mn |
| Mar 31, 2017 | 137.53 Mn |
| Dec 31, 2016 | 152.21 Mn |
| Sep 30, 2016 | 156.02 Mn |
| Jun 30, 2016 | 156.86 Mn |
| Dec 31, 2015 | 77.33 Mn |
| Dec 31, 2014 | 3.43 Mn |